I think the Aspire and Aruda shares were long since
I think the Aspire and Aruda shares were long since absorbed. I do not think that any selling from them is why the share price is low. Rather, every time the share price has started recovering, there has been a Mako attack, or a Rosen BS lawsuit, often at "coincidentally" the same time as an AF tweet.
There is no way that the selling of even millions of shares over two years accounts for this share price. The market cap is less than that of pre-clinical companies with only one class of drug in development, rather than 3 different drugs with multiple applications that are in thus-far successful clinical trials.
Having watched the tape go by on many occasions, it is clear that there has been a pattern of manipulation of stock price. Because the behavior of the trades during the day has suddenly changed, I think that there has been considerable short covering, and that the stock is poised for a move up. Also, the appearance of former bashers now attempting to pump the stock, or claiming always to have been bullish, indicates that at least one of the small-traders' gangs has changed sides.
In any case, I have utter confidence in the science, and I believe that when the move upward comes (which I don't expect until the fall, but of course I know nothing more than any other investor does), it will be shocking in its magnitude. Hopefully it will destroy any remaining short sellers when it does.
4
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...
Continue Reading
Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...
Continue Reading
Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...
Continue Reading
Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...
Continue Reading
A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...
Continue Reading